Trial intelligence / Profile preview

Methotrexate for chronic chondrocalcinosis

2007-003479-37Phase 4Completed

Sponsor: University Hospital of Geneva
Start: Oct 2007
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries: 1

Overview

Phase 4, randomised trial of methotrexate in chondrocalcinosis (CPPD) (2 arms), sponsored by University Hospital of Geneva. Primary endpoints: Disease activity measured by DAS 44, Pain and 2 more. Started Oct 2007; status: completed.

Drugs

methotrexate

Conditions

chondrocalcinosis (CPPD)

Beyond the preview

Go deeper on 2007-003479-37.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2007-003479-37.